鐮狀細胞貧血症全球市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計鐮狀細胞貧血症市場將從 2025 年的 99 億美元成長到 2034 年的 131.6 億美元，2026 年至 2034 年的複合年成長率為 3.22%。

由於人們對遺傳性血液疾病的認知不斷提高以及治療方法的進步，全球鐮狀細胞貧血市場正日益受到關注。鐮狀細胞貧血症是一種遺傳性疾病，會影響紅血球的形狀和功能，導致劇烈的陣發性疼痛和其他併發症。某些地區盛行率的上升以及篩檢計畫的擴大，正在推動對有效治療方法的需求。

醫學研發的進步是鐮狀貧血症市場成長的主要驅動力。基因療法、骨髓移植和新型緩解疾病藥物等創新治療方法正在改善患者的治療效果。各國政府和醫療機構也積極推廣早期診斷和管理項目，以減少疾病併發症。

隨著基因療法和個人化醫療研究的不斷深入，鐮狀細胞貧血症市場預計將顯著成長。旨在糾正潛在基因缺陷的突破性治療方法有望提供長期的解決方案。全球對罕見疾病治療日益成長的興趣以及醫療保健服務的改善將繼續推動市場發展。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球鐮狀細胞貧血症市場：依治療方法

• 市場分析、洞察與預測
• 骨髓移植
• 製藥
• 輸血
• 基因治療

第5章：全球鐮狀細胞貧血症市場：依通路分類

• 市場分析、洞察與預測
• 診所
• 醫院
• 家庭醫療保健

第6章 全球鐮狀細胞貧血症市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Bluebird Bio
  • Eli Lilly
  • Gilead SciencesInc
  • Merck & Co.Inc
  • Novartis AG
  • Sanofi
  • Baxter
  • Bristol-Myers Squibb Company
  • Global Blood Therapeutics
  • Johnson & Johnson
  • Mast Therapeutics
  • PfizerInc

The Sickle Cell Anemia Market size is expected to reach USD 13.16 Billion in 2034 from USD 9.90 Billion (2025) growing at a CAGR of 3.22% during 2026-2034.

The global sickle cell anemia market is gaining attention due to increasing awareness and advancements in the treatment of genetic blood disorders. Sickle cell anemia is an inherited condition that affects the shape and function of red blood cells, leading to severe pain episodes and other complications. Rising prevalence in certain regions and increasing screening programs are driving the demand for effective treatment solutions.

Advancements in medical research and drug development are major factors supporting the growth of the sickle cell anemia market. Innovative therapies such as gene therapy, bone marrow transplantation, and new disease-modifying drugs are improving treatment outcomes for patients. Governments and healthcare organizations are also promoting early diagnosis and management programs to reduce disease complications.

In the future, the sickle cell anemia market is expected to witness substantial growth due to ongoing research in genetic therapies and personalized medicine. Breakthrough treatments aimed at correcting the underlying genetic defect offer promising long-term solutions. Increasing global focus on rare disease treatment and improved healthcare access will continue to support market development.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapy types

• Bone Marrow Transplants
• Medications
• Blood Transfusions
• Gene Therapy

By Distribution channels

• Clinics
• Hospitals
• Home Healthcare

COMPANIES PROFILED

• Bluebird Bio, Eli Lilly, Gilead Sciences, Inc, Merck Co, Inc, Novartis AG, Sanofi, Baxter, BristolMyers Squibb Company, Global Blood Therapeutics, Johnson Johnson, Mast Therapeutics, Pfizer, Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SICKLE CELL ANEMIA MARKET: BY THERAPY TYPES 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Types
• 4.2. Bone Marrow Transplants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Blood Transfusions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SICKLE CELL ANEMIA MARKET: BY DISTRIBUTION CHANNELS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channels
• 5.2. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Home Healthcare Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SICKLE CELL ANEMIA MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Therapy Types
  • 6.2.2 By Distribution Channels
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Therapy Types
  • 6.3.2 By Distribution Channels
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Therapy Types
  • 6.4.2 By Distribution Channels
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Therapy Types
  • 6.5.2 By Distribution Channels
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Therapy Types
  • 6.6.2 By Distribution Channels
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL SICKLE CELL ANEMIA INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Bluebird Bio
  • 8.2.2 Eli Lilly
  • 8.2.3 Gilead SciencesInc
  • 8.2.4 Merck & Co.Inc
  • 8.2.5 Novartis AG
  • 8.2.6 Sanofi
  • 8.2.7 Baxter
  • 8.2.8 Bristol-Myers Squibb Company
  • 8.2.9 Global Blood Therapeutics
  • 8.2.10 Johnson & Johnson
  • 8.2.11 Mast Therapeutics
  • 8.2.12 PfizerInc